Qianqian Shi

Dr. Qianqian Shi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
QSQianqian Shi
Qianqian Shi
GSGuangyong Song
Guangyong Song
LSLiying Song
Liying Song
YWYu Wang
Yu Wang
JMJun Ma
Jun Ma
EYEnwu Yuan
Enwu Yuan
Extensive research has shown that PR domain 16 (PRDM16) plays a critical role in adipose tissue metabolism, including processes such as browning and thermogenesis of adipocytes, beigeing of adipocytes, and adipogenic differentiation of myoblasts. These functions have been associated with diseases such as obesity and diabetes. Additionally, PRDM16 has been correlated with various other conditions, including migraines, heterochromatin abnormalities, metabolic syndrome, cardiomyopathy, sarcopenia, nonsyndromic cleft lip, and essential hypertension, among others. However, there is currently no systematic or comprehensive conclusion regarding the mechanism of PRDM16 in human tumours, including haematologic and solid tumours. The aim of this review is to provide an overview of the research progress on PRDM16 in haematologic and solid tumours by incorporating recent literature findings. Furthermore, we explore the prospects of PRDM16 in the precise diagnosis and treatment of human haematologic and solid tumours.

15 July 2025 in Translational Oncology
Verified
Journal Article
Open access
QSQianqian Shi
Qianqian Shi
JGJinshuang Gao
Jinshuang Gao
HYHaiyang Yu
Haiyang Yu
YNYaodong Niu
Yaodong Niu
EYErfeng Yuan
Erfeng Yuan
LZLinlin Zhang
Linlin Zhang
Germline loss-of-function mutations in BRCA1 and BRCA2 (BRCA) genes are well-established as causative factors for hereditary breast and ovarian cancer (HBOC), conferring an approximately tenfold increased lifetime risk. The identification of BRCA mutations is essential for risk assessment and management in high-risk individuals and cancer patients. In this study, we utilized next-generation sequencing (NGS) to comprehensively analyze the entire coding regions of BRCA genes in a cohort of 100 unselected patients undergoing germline screening (average age ≤45 years and/or family history of related cancers). A total of twenty-two variants were identified, including thirteen pathogenic or likely pathogenic variants (PVs/LPVs) and nine variants of uncertain significance (VUSs). Notably, six novel variants (two in BRCA1 and four in BRCA2) were discovered. Molecular subtyping revealed that breast cancer (BC) patients with BRCA variants were predominantly human epidermal growth factor receptor-2 (HER2)-negative. Using in silico prediction tools, nine VUSs were reclassified, with functional impairment confirmed for the BRCA2 p.W2619C and BRCA2 p.N1023_I1024del variants. Functional assays demonstrated that the BRCA2 p.W2619C variant significantly enhanced cell proliferation, migration, and invasion. Moreover, cells harboring the BRCA2 p.W2619C mutation exhibited increased sensitivity to Olaparib, suggesting potential therapeutic benefit from PARP inhibitors for patients with this variant. Our study identified six novel BRCA mutations and functionally validated the pathogenicity of the BRCA2 p.W2619C variant, thereby advancing the understanding of BRCA-related cancer risk and supporting enhanced genetic counseling and testing strategies for at-risk populations.